Literature DB >> 21566963

Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations.

T Ito1, T Seyama, Y Hayashi, T Hayashi, K Dohi, T Mizuno, K Iwamoto, N Tsuyama, N Nakamura, M Akiyama.   

Abstract

New cell lines, designated 8305C and 8505C, were established from undifferentiated thyroid carcinomas of a 67 year-old-female patient and a 78-year-old-female patient, respectively. Pathologically both these primary undifferentiated carcinoma tissues contained residual well differentiated components, suggesting well differentiated to undifferentiated carcinoma progression. Cell kinetic analysis indicate that the cell population doubling time is 43 h for 8305C and 36 h for 8505C. The saturation density at confluency is 5.7 x 10(4) cells/cm2 for 8305C and 1.1 x 10(5) cells/cm2 for 8505C. To identify genetic changes that may have occurred in these two cell lines, tumor suppressor genes p53, Rb, APC and MCC were analyzed. Sequence analysis confirmed a C:G to T:A transition at the first base of p53 gene codon 273 in 8305C and a C:G to G:C transversion at the first base of p53 codon 248 in 8505C. Polymerase chain reaction-loss of heterozygosity assays confirmed allelic deletion of p53 gene from the 8505C cell line. Loss of heterozygosity of other tumor suppressor genes were not observed. Given that p53 mutations associate with undifferentiated carcinoma but not with well differentiated carcinoma during multistep carcinogenesis of the thyroid, these cell lines should prove useful for research into the role of p53 gene mutations in malignant transformation.

Entities:  

Year:  1994        PMID: 21566963     DOI: 10.3892/ijo.4.3.583

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  23 in total

1.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

2.  Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).

Authors:  Junaid Abdulghani; Prashanth Gokare; Jean-Nicolas Gallant; David Dicker; Tiffany Whitcomb; Timothy Cooper; Jiangang Liao; Jonathan Derr; Jing Liu; David Goldenberg; Niklas K Finnberg; Wafik S El-Deiry
Journal:  Clin Cancer Res       Date:  2016-06-15       Impact factor: 12.531

3.  Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.

Authors:  Zhilan Li; Xiudi Jiang; Peihong Chen; Xuebing Wu; Aihua Duan; Yiyu Qin
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

4.  B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Authors:  Carmelo Nucera; Alessandro Porrello; Zeus Andrea Antonello; Michal Mekel; Matthew A Nehs; Thomas J Giordano; Damien Gerald; Laura E Benjamin; Carmen Priolo; Efisio Puxeddu; Stephen Finn; Barbara Jarzab; Richard A Hodin; Alfredo Pontecorvi; Vânia Nose; Jack Lawler; Sareh Parangi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

5.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

6.  Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Alessandro Antonelli; Paola Orlandi; Silvia Martina Ferrari; Anna Fioravanti; Greta Alì; Gabriella Fontanini; Fulvio Basolo; Giulio Francia; Guido Bocci
Journal:  Cancer Lett       Date:  2017-09-28       Impact factor: 8.679

7.  Efficacy of adavosertib therapy against anaplastic thyroid cancer.

Authors:  Yu-Ling Lu; Yu-Tung Huang; Ming-Hsien Wu; Ting-Chao Chou; Richard J Wong; Shu-Fu Lin
Journal:  Endocr Relat Cancer       Date:  2021-04-29       Impact factor: 5.678

8.  RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer.

Authors:  S E Lee; J U Lee; M H Lee; M J Ryu; S J Kim; Y K Kim; M J Choi; K S Kim; J M Kim; J W Kim; Y W Koh; D-S Lim; Y S Jo; M Shong
Journal:  Oncogenesis       Date:  2013-07-15       Impact factor: 7.485

9.  Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

Authors:  Junaid Abdulghani; Joshua E Allen; David T Dicker; Yingqiu Yvette Liu; David Goldenberg; Charles D Smith; Robin Humphreys; Wafik S El-Deiry
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

10.  Downregulation of Notch-regulated Ankyrin Repeat Protein Exerts Antitumor Activities against Growth of Thyroid Cancer.

Authors:  Bing-Feng Chu; Yi-Yu Qin; Sheng-Lai Zhang; Zhi-Wei Quan; Ming-Di Zhang; Jian-Wei Bi
Journal:  Chin Med J (Engl)       Date:  2016-07-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.